Skip to content
Dx

ICD-10-PCS 2027 procedure code

3E06302Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach

✓ Valid for 2027Non-O.R. procedure

Short description: Introduce of High dose IL-2 into Central Art, Perc Approach

Code unchanged since ICD-10-PCS took effect on October 1, 2015. Source: official FY2027 ICD-10-PCS release from CMS. Page updated September 29, 2026. About our data

About 3E06302

3E06302 is the ICD-10-PCS code for a introduction procedure on the central artery using a percutaneous approach with antineoplastic (qualifier: high-dose interleukin-2). In ICD-10-PCS, introduction means putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

In plain terms, this corresponds to High-dose infusion interleukin-2 [IL-2], the ICD-9-CM procedure title it maps to (00.15).

For a different body part, codes include 3E03302 (peripheral vein), 3E04302 (central vein), 3E05302 (peripheral artery), 3E0R302 (spinal canal) and 3E0S302 (epidural space).

The same procedure with a different approach is coded 3E06002 (open).

It is a non-O.R. procedure that is part of the MS-DRG logic for DRG 837 (Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC) and DRG 838 (Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent), under the surgical category “Chemotherapy with Acute Leukemia As Secondary Diagnosis”.

It has been valid since ICD-10-PCS took effect on October 1, 2015.

What each character means

1. Section
3Administration
2. Body System
EPhysiological Systems and Anatomical Regions
3. Operation
0Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

4. Body System / Region
6Central Artery
5. Approach
3Percutaneous

Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure

6. Substance
0Antineoplastic

Includes: Amivantamab Monoclonal Antibody; Lurbinectedin; RYBREVANT (tm) (Amivantamab Monoclonal Antibody); ZEPZELCA(tm) (Lurbinectedin)

7. Qualifier
2High-dose Interleukin-2

Other versions of this procedure

Different approach

MS-DRG v44.0 grouping

All DRGs →

Surgical MS-DRGs this procedure can group to, depending on the principal diagnosis's MDC.

ICD-9-CM equivalent

Converter →
  • 00.15High-dose infusion interleukin-2 [IL-2]approximate

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
  • No changes since FY2016.

Common questions about 3E06302

Is 3E06302 a valid ICD-10-PCS code for 2027?

Yes. 3E06302 is valid for inpatient procedures from October 1, 2026 through September 30, 2027.

Is 3E06302 an O.R. procedure?

No. 3E06302 is designated non-O.R. in MS-DRG v44.0.

What DRG does 3E06302 group to?

Depending on the principal diagnosis, 3E06302 can group to MS-DRG 837 and MS-DRG 838.

What is the ICD-9 procedure code for 3E06302?

The CMS GEMs map 3E06302 to ICD-9-CM 00.15 (High-dose infusion interleukin-2 [IL-2]).